CDC42BPB Antibody

Code CSB-PA003270
Size US$100
Order now
Image
  • Western Blot analysis of COLO205 cells using MRCKβ Polyclonal Antibody
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
CDC42BPB
Alternative Names
CDC42 binding protein kinase beta antibody; CDC42-binding protein kinase beta antibody; CDC42BPB antibody; DMPK like beta antibody; DMPK-like beta antibody; KIAA1124 antibody; MRCK beta antibody; MRCKB_HUMAN antibody; Myotonic dystrophy kinase related CDC42 binding kinase beta antibody; Myotonic dystrophy kinase-related CDC42-binding kinase beta antibody; Myotonic dystrophy protein kinase like beta antibody; Myotonic dystrophy protein kinase-like beta antibody; Serine/threonine protein kinase MRCK beta antibody; Serine/threonine-protein kinase MRCK beta antibody
Raised in
Rabbit
Species Reactivity
Human,Mouse,Rat
Immunogen
Synthesized peptide derived from the C-terminal region of Human MRCKβ.
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Isotype
IgG
Purification Method
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Form
Liquid
Tested Applications
WB, IHC, ELISA
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:2000
IHC 1:100-1:300
ELISA 1:40000
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Serine/threonine-protein kinase which is an important downstream effector of CDC42 and plays a role in the regulation of cytoskeleton reorganization and cell migration. Regulates actin cytoskeletal reorganization via phosphorylation of PPP1R12C and MYL9/MLC2. In concert with MYO18A and LURAP1, is involved in modulating lamellar actomyosin retrograde flow that is crucial to cell protrusion and migration. Phosphorylates PPP1R12A. In concert with FAM89B/LRAP25 mediates the targeting of LIMK1 to the lamellipodium resulting in its activation and subsequent phosphorylation of CFL1 which is important for lamellipodial F-actin regulation.
Gene References into Functions
  1. these results provide further validation for MRCK involvement in regulation of cancer cell invasion. PMID: 21949762
  2. Cdc42-dependent formation of the ZO-1/MRCKbeta complex at the leading edge controls cell migration. PMID: 21240187
  3. Q-PCR results demonstrated VH2 genes were overexpressed in ankylosing spondylitis patients. The sequence analysis revealed the majority of them contained CDC42 binding protein kinase Beta (CDC42 BPB) genes. PMID: 20177145
Subcellular Location
Cytoplasm. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Cell junction. Cell projection, lamellipodium.
Protein Families
Protein kinase superfamily, AGC Ser/Thr protein kinase family, DMPK subfamily
Tissue Specificity
Expressed in all tissues examined, with high levels in heart, brain, placenta and lung.
Database Links

HGNC: 1738

OMIM: 614062

KEGG: hsa:9578

STRING: 9606.ENSP00000355237

UniGene: Hs.654634

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*